CG Oncology, Inc. Shareholders' Equity
CG Oncology, Inc. (CGON) had Shareholders' Equity of $1.03 billion as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-06
- 2026-06-30: Stockholders' Equity Attributable to Parent $1.03B.
- 2026-03-31: Stockholders' Equity Attributable to Parent $1.09B.
- 2025-12-31: Stockholders' Equity Attributable to Parent $752.60M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $687.64M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $1.03B 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $1.09B 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $752.60M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $687.64M 10-Q · filed 2025-11-14 | |
| 2025-06-30 | $670.36M 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $704.76M 10-Q · filed 2026-08-06 | |
| 2024-12-31 | $733.38M 10-Q · filed 2026-08-06 | |
| 2024-09-30 | $536.77M 10-Q · filed 2025-11-14 | |
| 2024-06-30 | $552.36M 10-Q · filed 2025-11-14 | |
| 2024-03-31 | $568.94M 10-Q · filed 2025-11-14 | $568.94M 10-Q · filed 2024-05-09 |
| 2023-12-31 | -$123.10M 10-K · filed 2026-02-27 | |
| 2023-09-30 | -$107.58M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | -$97.39M 10-Q · filed 2024-11-12 | |
| 2023-03-31 | -$86.12M 10-Q · filed 2024-11-12 | -$86.11M 10-Q · filed 2024-05-09 |
| 2022-12-31 | -$77.69M 10-K · filed 2026-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |